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Cutaneous involvement characterized by urticarial lesions with or without angioedema and itch is commonly
observed in routine medical practice. The clinical approach may still remain complex in real life, because several
diseases may display similar cutaneous manifestations. Urticaria is a common disease, characterized by the sudden
appearance of wheals, with/without angioedema. The term Chronic Urticaria (CU) encompasses a group of
conditions with different underlying causes and different mechanisms, but sharing the clinical picture of recurring
wheals and/or angioedema for at least 6 weeks. Hereditary Angioedema (HAE) is a rare disorder characterized by
recurrent episodes of non-pruritic, non-pitting, subcutaneous or submucosal edema affecting the extremities, face,
throat, trunk, genitalia, or bowel, that are referred as “attacks”. HAE is an autosomal dominant disease caused by a
deficiency of functional C1 inhibitor, due to a mutation in C1-INH gene (serping 1 gene) characterized by the clonal
proliferation of mast cells, leading to their accumulation, and possibly mediator release, in one or more organs.
In childhood there are two main forms of mastocytosis, the Systemic and the Cutaneous. The clinical features
of skin lesions in urticaria, angioedema and mastocytosis may differ depending on the aetiologic factors, and the
underlying pathophysiological mechanisms. The diagnostic process, as stepwise approach in routine clinical practice, is
here reviewed for CU, HAE and mastocytosis, resulting in an integrated method for improved management of these
cutaneous diseases. Taking into account that usually these conditions have also a relevant impact on the quality
of life of children, affecting social activities and behavior, the availability of care pathways could be helpful in disen-
tangle the diagnostic issue achieving the most cost-effective ratio.
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practiceIntroduction
Cutaneous involvement characterized by urticarial le-
sions with or without angioedema and itch is commonly
observed in routine medical practice, and often this ob-
servation poses important diagnostic challenges. In fact,
although the diagnostic processes are quite standardized,
based on scientific evidences [1], the clinical approach
may still remain complex in real life, because several dis-
ease may display similar cutaneous manifestations. For
instance, itching is useful in confirming the diagnosis of
urticaria, but itching is can also be a sign of other sys-
temic diseases, thus requiring additional investigations* Correspondence: giuliana.ferrante@unipa.it
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unless otherwise stated.for an accurate diagnostic process. Therefore, a compre-
hensive approach to the most common cutaneous aller-
gic diseases occurring in childhood is advised, to achieve
an optimal clinical management.
This review describes the clinical features of Urticaria,
Angioedema, and Mastocytosis in childhood, including epi-
demiology. The diagnostic process, as stepwise approach,
in routine clinical practice is reviewed for chronic urticaria
(CU), hereditary angioedema (HAE) and mastocytosis,
resulting in an integrated method for improved man-
agement of these cutaneous disease.Clinical aspects
Urticaria
Urticaria is a common disease, affecting 15-25% of the
population with at least one episode during lifetime. Inl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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United Kingdom the occurence of all forms of childhood
urticaria is around 3,4% [2], while in Germany it has
been estimated to be around 4,4% [3] and in Denmark
around 5,4% [4]. The prevalence of childhood chronic
urticaria is 0,1-0,3% in the United Kingdom [5], while in
a Thai study, 13% of children with urticaria were classi-
fied as having a chronic form [6].
A clinical classification of urticaria has been recently
published in a European Academy of Allergy and Clin-
ical Immunology (EEACI) guideline [7] (Table 1).
Urticaria is characterized by the sudden appearance of
pruritic wheals, with/without angioedema. A wheal con-
sists of three typical features: 1. a central swelling of
variable size, almost invariably surrounded by a reflex
erythema; 2. itching or, sometimes, burning sensation; 3.
a fleeting nature, with the skin returning to its normal
appearance, usually within 1–24 h. Urticaria is defined
as acute if wheals last less than 6 weeks, and chronic if
lasting 6 weeks or more [8]. The term Chronic Urticaria
(CU) encompasses a group of conditions with different
underlying causes and different mechanisms, but shar-
ing the clinical picture of recurring wheals and/or angio-
edema for at least 6 weeks [9]. Chronic Spontaneous
Urticaria (CSU) is defined as the daily or almost daily
occurrence of wheals for more than 6 weeks, after the
exclusion of physical urticaria and other urticarial
types [10].
CU in children is caused by physical factors in at least
6% of cases. Less often, infections (4%), foods (4%), additives
(2,65%), aeroallergens (2,2%) and drugs (1,6%), are trigger
factors [4]. Physical Urticaria (PU) is a heterogeneous sub-
group of chronic urticaria in which wheals can be induced
by various physical stimuli such as cold, heat, pressure, vi-
bration, or sunlight. It is common in young adults [10],
whereas in children cold urticaria is idiopathic or secondaryTable 1 Classification of urticaria subtypes (Modified From
EEACI guideline 2009)
Types Subtypes
Spontaneous urticaria Acute Spontaneous Urticaria (<6 weeks)
Chronic Spontaneous Urticaria (>6 weeks)
Physical urticaria Cold Contact Urticaria
Delayed Pressure Urticaria
Heat Contact Urticaria
Solar Urticaria
Urticaria Factitia/Dermographic Urticaria
Vibratory Urticaria/Angioedema
Other urticaria types Aquagenic Urticaria
Cholinergic Urticaria
Contact Urticaria
Exercise Induced Anaphylaxis/Urticariato viral infections [11]; in addition some atypical cold urti-
caria forms have been reported, being either hereditary or
acquired [12].
Other urticarial disorders include cholinergic, acqua-
genic, contact- and exercise-induced urticaria [8,9].
The formers, with typical small wheals (diameter of
less than 5 mm), appear within a few minutes after the
elevation of body temperature, independently of pas-
sive exposure to hot shower, or as a consequence of
physical exercise [13,14].
Angioedema
There are few epidemiological data about Angioedema
in children. In the only published study on children with
urticaria, wheals alone were present in 78,4%, angio-
edema alone in 6,65% and both in 15% [15]. Angioedema
is characterized by: 1. a sudden, pronounced swelling of
the lower dermis and subcutis; 2. sometimes pain rather
than itching; 3. frequent involvement of mucous mem-
branes; 4. slow resolution that can take up to 72 h [7].
Hereditary Angioedema (HAE) is a rare disorder
(Orpha number 91378, www.orpha.net) characterized
by recurrent episodes of non-pruritic, non-pitting, sub-
cutaneous or submucosal edema affecting the extrem-
ities, face, throat (tongue, larynx, and lips), trunk,
genitalia, or bowel, that are referred as “attacks”. Classic-
ally edema develops slowly, over a period of up to 36 hours
and completely resolve spontaneously within 4 days.
Swelling is usually self-limited and painless when af-
fecting the skin, whereas abdominal attacks with diar-
rhea, vomiting, and pseudo-obstructive syndrome are
painful, resulting sometimes in unnecessary surgery.
All attacks localized over the shoulders must be con-
sidered severe and potentially life-threatening [15]. In
some patients a mean interval of 8.3 hours between
onset and maximum development of laryngeal edema
was reported [16]. In the United States a HAE incidence
rate of 1:10,000-50,000 people has been reported, and a
recent study underlined the importance of diagnosis and
appropriate treatment, as the mortality of HAE patients
who had not been diagnosed was 29% compared to 3% in
those who had been diagnosed [17]. Moreover, a study
highlighted the high frequency of de novo mutations and
exon deletions in the C1inhibitor gene of patients with an-
gioedema without family history, suggesting important
and incoming acquisitions in the genetic epidemiology of
the disease [18].
HAE is an autosomal dominant disease caused by a
deficiency of functional C1 inhibitor (C1-INH), due to a
mutation in C1-INH gene (serping 1 gene) mapped to
chromosome 11(11q12-q 13.1). Bradykinin is the main
mediator implicated in edema [19]. Although more than
200 mutations of serping 1 gene have been linked to the
clinical HAE manifestations, only two account for the
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Type-1 HAE (Table 2).
Mastocytosis
Mastocytosis is a heterogeneous disorder characterized
by the clonal proliferation of mast cells (MCs), leading
to their accumulation, and possibly mediator release, in
one or more organs [21]. In childhood there are two
main forms of mastocytosis, the Systemic (SM) and the
Cutaneous (CM), this latter including three major vari-
ants: maculopapular cutaneous mastocytosis (MPCM),
diffuse cutaneous mastocytosis (DCM), and solitary mas-
tocytoma. The classification has been recently reviewed
by the World Health Organization (WHO) [22].
In Spain a prevalence of 5.4 cases per 1000 pediatric
dermatology patients was found, whereas in Mexico the
condition was seen in 1:500 first-time pediatric derma-
tology patients. Mastocytosis occurs in all ethnic groups
and may appear at any age. CM is more common in
children; a second smaller peak of incidence is seen in
adults in the third to fourth decade [23].
MPCM (urticaria pigmentosa) is the most common
clinical variant in which fixed, reddish brown lesions oc-
curring as maculo-papules, plaques, nodules or blisters
are found. These lesions urticate in response to physical
irritation (Darier’s sign). Urticaria Pigmentosa (UP) le-
sions tend to be larger, better delineated, and more hy-
perpigmented in children, as compared to adults, who
tend to have numerous small lesions that coalesce to
form mottled areas. The trunk and thigh are more com-
monly involved with sparing of face, palms and soles [21].
DCM is a rare variant of childhood mastocytosis that ap-
pears as diffuse infiltrative yellow-orange xanthogranuloma-
like subcutaneous nodules, or as a widespread urticarial
eruption with bullae and redness. The clinical course of
DCM is more severe than that of mastocytoma and MPCM
and can even be life-threatening, due to hypovolemic shock,
mast cell leukemia, gastrointestinal hemorrhage, and
cachexia [24].
The stepwise diagnostic approach
Chronic urticaria
A step by step diagnostic approach or chronic urticaria
is recommended, starting from the patient history andTable 2 HAE Classification
HAE 1 Low production of functionally
active C1-INH
HAE 2 Normal or elevated levels of C1-INH,
but with functional impairment of
the protein
HAE3 (irrelevant in
children and adolescent)
Mutations in the coagulation factor
XII. No abnormalities in C1-INH level
or functionphysical examination, in order to better address the sub-
sequent tests, some of which are performed to exclude
severe systemic diseases (Table 3).
First line
Clinical history, including all possible eliciting factors
and significant aspects of the origin of urticaria, is the
most important issue for a proper diagnostic process.
Some of the most frequently asked questions are re-
ported in Table 4. Several scoring systems have been
proposed using scales from 0–3 or up to 10 points. A
unified and simple scoring system, the Urticaria Activity
Score (UAS), was recently validated for the evaluation of
disease activity by patients and their treating physicians.
As urticarial symptoms frequently change in intensity,
overall disease activity is best measured by advising pa-
tients to document a 24-hour based self-evaluation score
for consecutive days. In CU patients the UAS score of
7 consecutive days should be used to assess the disease
activity and the treatment efficacy (Table 4) [7]. Clinical
symptoms must determine which laboratory tests could
be performed e.g., complete blood count, liver and renal
function tests, C-reactive protein levels, sedimentation
rate and urinalysis [1].
Second line
Additional investigations are suggested in the diagnostic
approach to CU and CSU. Although allergy is a rare
cause of CSU an allergy screening test should be consid-
ered in CSU patients with a personal history suggestive
of allergic diseases. Chronic persistent bacterial, viral
parasitic and fungal infections that may trigger urticarial
symptoms in patients with CSU should be considered,
only according to the patient’s history [7]. Total immuno-
globulin count and antinuclear factor should be considered
in patients with single hives that lasts >24 hours, to rule
out vasculitis whereas biopsy is rarely necessary (patients
with one or more of the following features: individual pain-
ful lesions with purpuric or petechial characteristics that
last >24 hours, elevated C-reactive protein levels and/or
systemic symptoms such as fever and arthralgias, unre-
sponsiveness to appropriate doses of antihistamines) [8,25].
In Physical Urticaria the routine diagnosis is mainly aimed
at the identification of the subtype of the urticaria through
the appropriate physical stimulation tests and to the deter-
mination of trigger thresholds [7].
Since autoimmune diseases, like celiac or thyroid dis-
ease are commonly reported in children with CU, la-
boratory tests for these diseases should be done [10].
Recent publications have shown 30-50% of patients with
CSU produce an immunoglobulin IgG type autoantibody
against either the high affinity receptor FcERIα or IgE.
However, the utility of the Autologous Serum Skin
Test (ASST) remains unclear in identifying a distinct
Table 3 First and second tools of chronic urticaria
Tools Chronic urticaria
First line •Relevant questions:
Q1. time of onset of disease
Q2. frequency and duration of wheals
Q3. diurnal variation
Q4. shape, size, and distribution of wheals
Q5. associated angioedema
Q6. associated subjective symptoms of lesion
Q7. family and personal history regarding urticarial atopy
Q8. previous or current allergies, infections, internal
diseases, or other possible causes
Q9. psychosomatic and psychiatric diseases
Q10. surgical implantations and events during surgery
Q11. gastric/intestinal problems (stool, flatulence)
Q12. induction by physical agents or exercise
Q13. use of drugs (nsaids, injections, immunizations,
hormones, laxatives, suppositories, ear and eye
drops, and alternative remedies)
Q14. observed correlation to food
Q15. relationship to the menstrual cycle
Q16. smoking habits
Q17. type of work
Q18. hobbies
Q19. stress (eustress and distress)
Q20. occurrence in relation to weekends, holidays, and
foreign travel
Q21. quality of life related to urticaria and emotional
impact
Q22. previous therapy and response to therapy
•Physical examination
•According to symptoms: Complete blood count, liver
and renal function tests, C-reactive protein levels and
sedimentation rate urinalysis
Second line Vasculitis: Ig, antinuclear factor, immune complex,
skin biopsy
Infections: Serologic studies for: HCV,HBV; HAV, EBV,
Mycoplasma Pneumoniae. Cultures, fecal antigen of
Helycobacter Pylori or Urea breath test.
Allergic: IgE, skin tests, eosinophil count, challenge,
elimination diet, tryptase.
Hereditary angioedema: C3,C4, C1 esterase inhibitor.
Physical: Methacolin test, running test, ice cube test, UV
and visible light exposure, dermographism, pressure test,
warm water immersion test.
Autoimmune chronic urticaria: Autologous serum
skin test (ASST), basophil histamine release test (BHRT).
Other: FT3,FT4, TSH, thyroid autoantibodies, celiac
screening.
Table 4 Assessment of disease activity patients with
urticaria
Score Wheals Pruritus
0 None None
1 Mild (<20/24 h) Mild
2 Moderate (20-50/24 h) Moderate
3 Intense (>50/24 h) Intense
Sum of score: 0–6.
(Modified From EEACI guideline 2009).
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history and response to treatment. So, current evi-
dence does not support routine performance of this
test in patients with CU [26].
Some other conditions should be considered in the diag-
nostic process mainly when an immunocomplex-induced
disease is suspected. These include serum sickness or
autoimmune diseases (Figure 1). When isolated angio-
edema is present, the assessment of C4 and C1 esterase
inhibitor levels should be performed [8].Hereditary angioedema (HAE)
According to the 2010 International Consensus algo-
rithm for diagnosis, therapy and management of HAE,
the diagnosis should be confirmed by measuring serum
complement factor 4 (C4) and serum C1-inhibitor pro-
tein and its functional levels [27]. Therefore, according
to the above section, the diagnostic pathway is showed
as first line and second line tools (Table 5, Figure 2).Mastocytosis
Mastocytosis is essentially suspected on clinical ground,
(including identification of UP lesions and recognition of
compatible MC mediator-related symptoms). Because
mastocytosis is due to a clonal proliferation of MCs, the
diagnosis is established by detection of MCs with abnor-
mal morphologic features and immunophenotypes in the
bone marrow or other extracutaneous organs and inves-
tigating specific mutations in its growth factor (c-KIT)
receptor [21].
The SCORMA (SCORing Mastocytosis) Index provides
a standardized information on the severity of CM. It is a
clinical scoring system based on a semi-quantitative ana-
lysis of extent, intensity and subjective complains, with no
burden for patients, which is particularly important in
children. The simultaneous assessment of SCORMA
Index and tryptase level is essential in all cases of
pediatric mastocytosis [23]. In Table 6 and Figure 3 the
first line and second line of diagnostic tools and the
diagnostic pathway process are respectively showed
(Table 6, Figure 3). In some patients with increased tryp-
tase level but not cutaneous signs of mastocytosis levels of
Children with wheals associated or not with angioedema
History and physical examination
Hives > 6 weeks
Acute Urticaria
No
Yes
Chronic Urticaria
Suspect of Physical urticaria 
YesNo
Consider other triggers
(infection, drugs, allergy, food) Confirm with a specific test Diagnosis and treatment
Yes
No
Specific examination
Yes
Specific diagnosis
Yes
Specific therapy
No a specific diagnosis Symptomatic therapy
Figure 1 The diagnostic pathway of Urticaria. Although allergy is a rare cause of CSU an allergy screening test should be considered in CSU
patients with intermittent symptoms and a suggestive history. Chronic persistent bacterial, viral parasitic and fungal infections that may trigger
urticarial symptoms in patients with CSU should be considered, only according to the patient’s history [7]. Total immunoglobulin count,
antinuclear factor and skin biopsy should be considered in patients with single hives that lasts >24 hours, to rule out vasculitis or Schnitzler
syndrome [8]. In Physical Urticaria the routine diagnosis is mainly aimed at the identification of the subtype of the urticaria through the
appropriate physical stimulation tests and to the determination of trigger thresholds [7]. Since CU in children may be associated with
autoimmune diseases, like celiac or thyroid disease, some Authors suggest to screen for them [9]. 30-50% of patients with CSU produce an
immunoglobulin IgG type autoantibody against either the high affinity receptor FcERIα or IgE. However, the utility of the Autologous Serum
Skin Test (ASST) remains unclear in identifying a distinct subgroup of patients with CU and in predicting natural history and response to
treatment. So, current evidence does not support routine performance of this test in patients with CU [26]. Some other conditions should
be considered in the diagnostic process mainly when an immunocomplex-induced disease is suspected. These include serum sickness or
autoimmune diseases. When isolated angioedema is present, the assessment of C4 and C1 esterase inhibitor levels should be performed [8].
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tabolites (like methylhistamine, NMH or methylimidazole
acetic acid, MIMA) and prostaglandin D2, may be increased
[28]. In childhood mastocytosis, measurement of the urinary
NMH level may be useful at the time of diagnosis high levels
of NMH suggesting more severe and extensive disease and
possible systemic involvement [29].Table 5 First and second line diagnostic tools of
hereditary angioedema
Tools Hereditary angioedema
First line Clinical presentation: recurrent angioedema or
abdominal pain in the absence of hives, without
urticaria
Family history
Laboratory: C4 and C1 inhibitor serum levels
Second line Genetic analysis: mutations in C1-INH gene
(Serping1 gene), mapped to chromosome
11 (11q12-q13.1)The stepwise management
Urticaria
The identification and elimination of eliciting factors is
the mainstay approach for urticaria treatment, also con-
sidered the special issue of the avoidance of physical
stimuli for the treatment of physical urticaria (PU). Since
the CSU is often reported to be associated with a variety
of inflammatory or infectious diseases, the proper treat-
ment for these underlying conditions should be advised.
Although, IgE-mediated food allergy is rarely the under-
lying cause of chronic spontaneous urticaria, after a con-
firmed diagnostic tests, the specific food allergens need
to be omitted as far as possible [30].
First line
In agreement with the most recent international guide-
lines, non-sedating second generation antihistamines are
recommended as first line symptomatic treatment. These
drugs have shown to be effective in numerous randomized
Family history of angioedema
Angioedema without urticaria
Clinical signs of HAE
C4,C1 ,C1 –INH serum level             
Normal C4   C1-INH  C4 Normal o C1-INH
Idiopathic HAE
Drugs HAE
HAE III
HAE I C1-INH Function
C1 –INH Function
HAE II
Figure 2 The diagnostic pathway of Hereditary Angioedema (HAE). According to the 2010 International Consensus algorithm for diagnosis,
therapy and management of HAE, the diagnosis should be confirmed by measuring serum complement factor 4 (C4) and serum C1-inhibitor
protein and its functional levels [27].
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tamines are equally effective, but they have pronounced
anticholinergic and sedative effects which last longer than
12 h, whereas the antipruritic effects last only 4–6 h. In
addition, first generation antihistamines can interfere with
rapid eye movement sleep, and impact on learning and
performance. Thus, the use of first generation antihista-
mines is discouraged [31].
Second line
The second level of therapy includes increasing the dos-
age of non-sedating second-generation antihistamines.
Their mode of action offers the best risk to benefit out-
come, in comparison to alternative treatments. At the III
level, guidelines recommend to change the non-sedating
antihistamine used in level II or to add antileukotriens,Table 6 The first and the second line diagnostic tools of
mastocytosis
Tools Mastocytosis
First line Complete blood cell count
Complete metabolic panel
Serum Tryptase level
Second line Abdominal ultrasound
Thoracic X ray
Bone marrow biopsy and aspirateas well as a short course of corticosteroids (3 days). At level
IV, different treatment options are suggested. H2 antihista-
mines in combination with H1 antihistamines have a low
evidence-based support, whereas more data are available
for dapsone and cyclosporine A. However the most effect-
ive drug at level IV treatment is Omalizumab [31].
Omalizumab diminished clinical symptoms and signs of
chronic idiopathic urticaria in patients who had remained
symptomatic despite the use of approved doses of
H1-antihistamines. Histamine release from cutaneous
mast cells has long been associated with the patho-
genesis of urticaria, whereas in patients with chronic
idiopathic urticaria, basophils and IgE may also play
an important role. Omalizumab, reduces the levels of
free IgE and the high-affinity receptor for the Fc re-
gion of IgE (FcεRI), both of which are essential in
mast-cell and basophil activation. Studies have shown
that omalizumab may suppress allergen-mediated skin re-
actions through its reduction of FcεRI function in baso-
phils and mast cells [32] (Table 7). A study from Maurer
et al. found that omalizumab administered as three doses
of 75 mg, 150 mg or 300 mg at 4-week intervals sig-
nificantly reduced symptoms, as compared with pla-
cebo, in patients with chronic idiopathic urticaria who
remained symptomatic despite the use of approved doses
of H1-antihistamines. Clinically meaningful effects were
seen for patients receiving either 150 mg or 300 mg of
Skin lesions or suggestive clinical 
Serum Tryptase
Complete blood cell count
Complete metabolic panel
Normal complete blood cell count 
Serum Tryptase ≤ 100 ng/ml
Abnormal complete blood cell count 
Serum Tryptase > 100 ng/ml
Bone marrow: biopsy and aspirateCutaneous mastocytosis
YesNo
Other Diagnosis Systemic Mastocytosis
Figure 3 The diagnostic pathway of Mastocytosis. Mastocytosis is essentially suspected on clinical ground. Because mastocytosis is due to a
clonal proliferation of MCs, the diagnosis is established by detection of MCs with abnormal morphologic features and immunophenotypes in the
bone marrow or other extracutaneous organs and investigating specific mutations in its growth factor (c-KIT) receptor [21]. The SCORMA Index
provides a standardized information on the severity of CM, with no burden for patients, which is particularly important in children. The simultaneous
assessment of SCORMA Index and tryptase level is essential in all cases of pediatric mastocytosis [23].
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itch-severity score (primary end point) and all secondary
end points at week 12, with the exception of the propor-
tion of angioedema-free days during week 4 through week
12 in the group receiving 150 mg of the drug [32]. The
therapeutic utility of omalizumab for refractory CU is as-
sociated with a relatively low rate of clinically significant
adverse effects. Hence omalizumab, which use has been
approved by the FDA at both 150 mg and 300 mg doses
in CU patients unresponsive to H1 antagonists 12 years of
age and older, is an alternative therapy to consider if theTable 7 First and second line therapy
Chronic urticaria therapy
I level therapy:
• Elimination of possible eliciting factors
• Non-sedating second generation antihistamines (nsAH)
If symptoms persist after 2 weeks
II level: Updosing of nsAH(X four times)
If symptoms persist after 4 weeks
III level: Add Leukotriene antagonist or change nsAH
If symptoms persist after 1–4 weeks
IV level: Add ciclosporin, H2 Antistamine, Dapsone, Omalizumab
During exacerbation: systemic steroid for 3–7 days in all levelscost-benefit ratio is favorable and if this approach is con-
sistent with patients’ preferences [11,33].
Overall, the disease activity should be evaluated at
regular intervals, in order to reduce the therapy. After
three months of complete response the intensity treat-
ment might be reduced [31].Hereditary angioedema (HAE)
The main treatment of HAE is represented by the control
of acute attacks, as well as short-term and long-term pro-
phylaxys [34]. Short-term prophylaxis is intended to pro-
tect against an angioedema attack for an important event
or for a known trigger. Triggers include dental proce-
dures, surgical procedures, and stressful life events
(including in family members, exam times, etc.). Long-
term prophylaxis is used to prevent attacks and is indi-
cated for patients with frequent (more than 24 days per
year with angioedema symptoms even if mild, or more
than 12 severe attacks per year) or severe attacks, past la-
ryngeal attacks, excessive loss of work or school, signifi-
cant anxiety, and poor quality of life [30]. The drug of
choice for children is tranexamic acid. Due to safety con-
cerns, androgen therapy for long-term prophylaxis in chil-
dren is not usually recommended [27,34].
The first-line therapy for HAE attacks in most countries
includes replacement therapy with C1-INH concentrate
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purified, pasteurized and lyophilized plasma-derived
C1-INH concentrate that has been approved in more
than 30 countries including United States (2009) and
Canada (2010) [36]. The largest randomized, double-blind,
prospective, placebo controlled study, called International
Multicenter Prospective Angioedema C1-inhibitor Trial
(I.M.P.A.C.T), confirmed the efficacy and safety of this.
The I.M.P.A.C.T.1 trial demonstrated that 20 U/kg C1-INH
concentrate is effective in treating acute abdominal and
facial HAE attacks [37]. I.M.P.A.C.T.2 was an open-
label extension study of I.M.P.A.C.T.1 to evaluate the
safety and efficacy of long-term treatment with C1-INH
concentrate for successive HAE attacks at anybody
location [36]. New drugs such as icatibant (a bradyki-
nin B2-receptor antagonist) and ecallantide (a plasma
kallikrein inhibitor) have been developed in recent
years. These drugs are not yet available in all coun-
tries and are not yet licensed for children. Ecallantide
has received a box- warning in the labeling, stating
that the drug should not be used as home therapy, be-
cause of possible hypersensitivity reactions including
anaphylaxis [38]. Studies in children and adolescents
are required [37].
Among the available new treatment modalities for long-
term prophylaxis, plasma-derived C1-esterase inhibitor
(pdC1-INH) concentrates represent an alternative treat-
ment for prevention of HAE attacks. Experimental results
showed that outcomes with pd C1 INH treatment of HAE
in pediatric patients are comparable to adults [39].
The Food and Drug Administration (FDA) has approved
the chronic prophylactic use of nano-filtered C1-inhibitor
(nfC1-INH) based on limited data, and it will be import-
ant that physicians monitor adverse events carefully. Thus
far, it appears that the chronic use of C1-INH is safe and
effective [27]. Recent studies concluded that in children
nfC1 INH was well tolerated, provided relief from symp-
toms of hereditary angioedema attacks, and reduced the
rate of attacks [40].
The recent literature showed that patients with frequent
attacks may benefit from long term prophylaxis. A study
evaluated the safety and prophylactic effect of weekly ad-
ministrations of recombinant C1 INH (rC1 INH). Weekly
administrations of 50 U/Kg rhC1INH appeared to reduce
the frequency of HAE attacks and were safe and well
tolerated [41].
Fresh Frozen Plasma (FFP) is often used for treatment
of HAE attacks and for short term prophylaxis. How-
ever, the use of FFP should be reserved when C1-INH,
icatibant or ecallantide are not available. The appropriate
use of disease-specific treatments for HAE improve pa-
tients' quality of life and reduce HAE-associated morbidity
and mortality. However, many of the newer treatments
represent financial challenges due to high costs, which arenot always balanced by the reduction of other medical
expenses [27].
Mastocytosis
Usually, isolated CM needs no treatment or action to be
taken. CM with cosmetic complaints should be treated
by a topical therapy only in children older than 2 years.
When CM is confined to about 10% of body surface, oc-
clusive dressing is used. When the extension is larger,
(more than 10%) the occlusive dressing is optional, and
usually the corticosteroid cream is diluted [42].
In CM with complaints of itch, redness and swelling,
avoiding foods with a possible triggering role has to be
suggested. Finally, also a systemic therapy with H1-and
H2-blocker (and oral sodium cromoglycate) may be
useful [43].
DCM is self-limiting, and the need for a treatment is
questionable. If DCM causes significant distress, leads to
frequent hospitalizations, or is life-threatening, treat-
ment with imatinib is a good option. Imatinib mesylate,
a type II kinase inhibitor, inhibits cell proliferation and
induces apoptosis by binding the adenosine triphosphate
pocket and the adjacent site of the kinase. The nonselec-
tivity of imatinib also explains side effects such as car-
diomyopathy and reduced growth velocity, the latter
being a relevant side effect in children. Other side effects
include nausea, vomiting, diarrhea, increased liver en-
zymes, hypophosphatemia, edema, skin rash, granulocy-
topenia, anemia, and thrombocytopenia, but these are
rare in children. A dose of 200 mg/m2/day have been
used in children, and reducing the dosage as soon as
sustained healing of the skin lesions is noted is sufficient
to obtain remission. Monitoring of peripheral blood,
liver function, cardiotoxicity, and growth velocity is
necessary [24].
Conclusion
The clinical features of skin lesions in urticaria, angio-
edema and mastocytosis may differ depending on the
aetiologic factors, and the underlying pathophysiological
mechanisms. For this reason, in routine clinical practice
itching and cutaneous lesions generally represent a heavy
challenge for the pediatrician in terms of scientific know-
ledge and use of proper diagnostic procedures, taking into
account that usually chronic urticaria have also a relevant
impact on the quality of life of children, affecting social
activities and behavior. Hence, the availability of care
pathways for urticaria, angioedema and mastocytosis
could be helpful in disentangle the diagnostic issue
achieving the most cost-effective ratio.
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